Company intelligence / Profile preview
Kemia
San Diego, California, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Kemia developed oral small molecule drugs using proprietary chemistry platforms focused on underexploited target classes such as alpha helix interactions and allosteric kinases. Its lead candidate KC706 was a p38 MAPK inhibitor that reached Phase 2 trials in pemphigus vulgaris but was discontinued. The company is now dissolved.
- Therapeutic areas
- CardiovascularDermatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Kemia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kemia.